Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

Miner, Philip B.; Orr, William C.; Filippone, Joseph; Jokubaitis, Leonard; Sloan, Sheldon

doi:10.1111/j.1572-0241.2002.05769.x

Cited by 140 publications

(50 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of PPIs in the management of nighttime heartburn has been documented in placebo-controlled studies [20, 21]. In the US Gallup survey, satisfaction with prescription medication was markedly higher than with over-the-counter medication or with lifestyle changes such as avoiding meals before going to bed or elevating the head of the bed [7].…”

Section: Discussionmentioning

confidence: 99%

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

et al. 2008

View full text Add to dashboard Cite

Background: Gastroesophageal reflux disease (GERD) is a common disorder. The aim of our study was to describe the prevalence of nighttime heartburn and its associations with esophagitis, Barrett’s esophagus, and extra-esophageal symptoms. Methods: Data were collected as part of the ongoing Progression of Gastroesophageal Reflux Disease (ProGERD) study. Based on endoscopy results, patients were categorized as having nonerosive GERD, erosive GERD, or Barrett’s esophagus. ORs and 95% CIs derived from logistic regression analysis were calculated for the association between nighttime heartburn and GERD complications. Results: The overall prevalence of nighttime heartburn for at least 1 of 3 years was 49%, and 21% of patients reported nighttime heartburn in all 3 years. According to multivariate analysis, chronic nighttime heartburn was associated with globus sensation (OR 1.79, 95% CI 1.29–2.47) and erosive GERD (OR 1.67, 95% CI 1.29–2.15). Compared to continuous proton pump inhibitor (PPI) intake, noncontinuous PPI therapy (OR 2.26, 95% CI 1.73–2.96) and medication other than PPIs (OR 2.46, 95% CI 1.67–3.62) were also associated with chronic nighttime heartburn. Conclusions: The prevalence of nighttime heartburn in GERD patients under routine care was high, even in patients on continuous PPI therapy. Nighttime heartburn was not associated with Barrett’s esophagus or most extra-esophageal symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Further definitions of symptom relief used in other clinical trials are [12,13,14]: (1) median time to achieve the first 24-hour interval without heartburn; (2) satisfactory heartburn relief: no ore than one episode of moderate severity during a preceding interval of seven days; (3) time to first and sustained resolution of heartburn; (4) total relief of symptoms on the fourth day of treatment defined as no or only mild heartburn, and (5) no more than one episode of moderate heartburn during 7 days.…”

Section: Examplesmentioning

confidence: 99%

Process of Measuring in Clinical Medicine – Implications of Different Definitions in Clinical Therapeutic Studies

Beckerling

Braun²,

Sommer³

2007

Digestion

View full text Add to dashboard Cite

Often, the decision whether a patient can be considered as healthy or ill is very difficult and depends on measurements and the interpretation of the results. Therefore, it is necessary to build and establish devices that base on certain pre-considerations (who should assess the data, when and how should be measured). Additionally, these devices have to be valid, reliable and responsive. According to the literature we came to the conclusion that no uniform definition of what is ‘healthy’ exists. Referring to mathematical considerations we show an approach to solve this problem especially when the device is a scale. Based on the quality of the scale and of certain pre-considerations, normal ranges can be established that will help to distinguish whether patients are ‘healthy‘ or ‘ill’. In this short review we discuss the problem of the establishment of a cut-off level on the basis of devices and we try to point out a solution to solve the arising problems.

show abstract

“…The efficacy of PPI therapy in the treatment of nighttime GERD symptoms has been well documented [27,28,29,30,31,32]. It should be noted that direct comparisons from study to study with regard to the comparative efficacy of PPI drugs in specifically treating nighttime reflux may be difficult due to major differences in how nighttime reflux is defined and how the data are presented.…”

Section: Introductionmentioning

confidence: 99%

“…Several placebo-controlled or open-label studies of rabeprazole have also confirmed its efficacy in the treatment of nighttime GERD symptoms [30,31,32]. A randomized, placebo-controlled trial of patients with endoscopically-negative GERD demonstrated that the time to the first nighttime heartburn-free interval was 1.5 days with rabeprazole 10 mg and 2.5 days with rabeprazole 20 mg, vs. 15.0 days for placebo [30].…”

Section: Introductionmentioning

confidence: 99%

“…A randomized, placebo-controlled trial of patients with endoscopically-negative GERD demonstrated that the time to the first nighttime heartburn-free interval was 1.5 days with rabeprazole 10 mg and 2.5 days with rabeprazole 20 mg, vs. 15.0 days for placebo [30]. Another randomized placebo-controlled trial of rabeprazole 20 mg showed significant differences in the rates of satisfactory relief of nighttime heartburn (no heartburn or mild heartburn) in favor of rabeprazole as early as day 2.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic Options in the Treatment of Nighttime Gastroesophageal Reflux

Orr

2005

Digestion

View full text Add to dashboard Cite

Approximately three quarters of individuals who suffer from gastroesophageal reflux disease (GERD) experience its symptoms at night. Nighttime GERD symptoms disturb sleep and diminish quality of life more so than daytime symptoms. Nighttime gastroesophageal reflux is common in individuals with respiratory disorders such as sleep apnea and asthma, and may affect the severity and the frequency of these disorders. The treatments of choice for nighttime GERD symptoms are proton pump inhibitors (PPIs) due to their efficacy in relieving day- and nighttime GERD symptoms and controlling acid secretion. The onset of action, degree of acid suppression, and duration of effect of PPIs have important implications for the use of these therapies in clinical practice. PPIs that exhibit rapid and prolonged control of acid secretion may be particularly useful for treating nighttime GERD symptoms.

show abstract

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

Abstract: Based on these findings and prior studies, rabeprazole reliably relieves GI symptoms equally well in both nonerosive GERD and erosive GERD.

Cited by 140 publications

References 25 publications

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

Nighttime Heartburn in Patients with Gastroesophageal Reflux Disease under Routine Care

Process of Measuring in Clinical Medicine – Implications of Different Definitions in Clinical Therapeutic Studies

Therapeutic Options in the Treatment of Nighttime Gastroesophageal Reflux

Contact Info

Product

Resources

About